tetano
Editor, Senior Moderator
Cells
. 2023 Sep 1;12(17):2191.
doi: 10.3390/cells12172191. Changes in the Proteome of Platelets from Patients with Critical Progression of COVID-19
Monika Wolny[SUP] 1 [/SUP], Svitlana Rozanova[SUP] 2 3 [/SUP], Cornelius Knabbe[SUP] 1 [/SUP], Kathy Pfeiffer[SUP] 2 3 [/SUP], Katalin Barkovits[SUP] 2 3 [/SUP], Katrin Marcus[SUP] 2 3 [/SUP], Ingvild Birschmann[SUP] 1 [/SUP]
Affiliations
Platelets, the smallest cells in human blood, known for their role in primary hemostasis, are also able to interact with pathogens and play a crucial role in the immune response. In severe coronavirus disease 2019 (COVID-19) cases, platelets become overactivated, resulting in the release of granules, exacerbating inflammation and contributing to the cytokine storm. This study aims to further elucidate the role of platelets in COVID-19 progression and to identify predictive biomarkers for disease outcomes. A comparative proteome analysis of highly purified platelets from critically diseased COVID-19 patients with different outcomes (survivors and non-survivors) and age- and sex-matched controls was performed. Platelets from critically diseased COVID-19 patients exhibited significant changes in the levels of proteins associated with protein folding. In addition, a number of proteins with isomerase activity were found to be more highly abundant in patient samples, apparently exerting an influence on platelet activity via the non-genomic properties of the glucocorticoid receptor (GR) and the nuclear factor κ-light-chain-enhancer of activated B cells (NFκB). Moreover, carbonic anhydrase 1 (CA-1) was found to be a candidate biomarker in platelets, showing a significant increase in COVID-19 patients.
Keywords: COVID-19; ECMO; NFκB; acute-phase proteins; carbonic anhydrase 1; glucocorticoid receptor; inflammation; mass spectrometry; platelets; proteomics.
. 2023 Sep 1;12(17):2191.
doi: 10.3390/cells12172191. Changes in the Proteome of Platelets from Patients with Critical Progression of COVID-19
Monika Wolny[SUP] 1 [/SUP], Svitlana Rozanova[SUP] 2 3 [/SUP], Cornelius Knabbe[SUP] 1 [/SUP], Kathy Pfeiffer[SUP] 2 3 [/SUP], Katalin Barkovits[SUP] 2 3 [/SUP], Katrin Marcus[SUP] 2 3 [/SUP], Ingvild Birschmann[SUP] 1 [/SUP]
Affiliations
- PMID: 37681923
- PMCID: PMC10486756
- DOI: 10.3390/cells12172191
Platelets, the smallest cells in human blood, known for their role in primary hemostasis, are also able to interact with pathogens and play a crucial role in the immune response. In severe coronavirus disease 2019 (COVID-19) cases, platelets become overactivated, resulting in the release of granules, exacerbating inflammation and contributing to the cytokine storm. This study aims to further elucidate the role of platelets in COVID-19 progression and to identify predictive biomarkers for disease outcomes. A comparative proteome analysis of highly purified platelets from critically diseased COVID-19 patients with different outcomes (survivors and non-survivors) and age- and sex-matched controls was performed. Platelets from critically diseased COVID-19 patients exhibited significant changes in the levels of proteins associated with protein folding. In addition, a number of proteins with isomerase activity were found to be more highly abundant in patient samples, apparently exerting an influence on platelet activity via the non-genomic properties of the glucocorticoid receptor (GR) and the nuclear factor κ-light-chain-enhancer of activated B cells (NFκB). Moreover, carbonic anhydrase 1 (CA-1) was found to be a candidate biomarker in platelets, showing a significant increase in COVID-19 patients.
Keywords: COVID-19; ECMO; NFκB; acute-phase proteins; carbonic anhydrase 1; glucocorticoid receptor; inflammation; mass spectrometry; platelets; proteomics.